Type 1 diabetes (T1D) results from an autoimmune destruction of insulin-producing β cells. Currently, the only curative therapy for late-stage T1D is islet transplantation. Even under chronic immunosuppression the beneficial effect is temporary. Apart from a severe shortage of donor islets, there is chronic graft rejection. Recent researches have revealed that autoimmunity of induced mixed chimerism reverses new-onset and results in the elimination of insulitis. The latest findings reveal that administration of gastrin and epidermal growth factor (EGF) also reverses new-onset but not late-stage T1D in the animal model. The findings published by 16 scientists in the latest issue i.e. May 9 2012 of Sci Transl Med Vol. 4, Issue 133 under the title “Mixed Chimerism and Growth Factors Augment β Cell Regeneration and Reverse Late-Stage Type 1 Diabetes” indicate that combination of therapy of induced mixed chimerism under a radiation-free regimen and administration of gastrin/EGF may boost both β cell neogenesis and replication. In other words, this treatment results in reversal of late-stage T1D in non obese diabetic mice. Its successful application into humans may replace the present day therapy of islet transplantation as a long-term restorative treatment for T1D.